University at Buffalo - The State University of New York
Skip to Content
The potential of p38 MAPK inhibitors to modulate periodontal infections. - PubMed - NCBI
Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Drug Metab. 2009 Jan;10(1):55-67.

The potential of p38 MAPK inhibitors to modulate periodontal infections.

Author information

1
Department of Craniofacial Biology, Center for Oral Health Research, Medical University of South Carolina, Charleston, SC 29425, USA. klkirk@musc.edu

Abstract

Periodontal disease initiation and progression occurs as a consequence of the host immune inflammatory response to oral pathogens. The innate and acquired immune systems are critical for the proper immune response. LPS, an outer membrane constituent of periodontal pathogenic bacteria, stimulates the production of inflammatory cytokines IL-1beta, TNFalpha, IL-6 and RANKL either directly or indirectly. In LPS-stimulated cells, the induction of cytokine expression requires activation of several signaling pathways including the p38 MAPK pathway. This review will discuss the significance of the p38 MAPK pathway in periodontal disease progression and the potential therapeutic consequences of pharmacological antagonism of this pathway in the treatment of periodontal diseases.

PMID:
19149513
PMCID:
PMC2810486
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Bentham Science Publishers Ltd. Icon for PubMed Central
    Loading ...
    Support Center